Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
Multi-specific antibodies
Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...
Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...
Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference
China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...
Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review
The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
Duality Biologics, a developer of novel modality drugs operating in the United States and China,...
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...